Description_x000D_ General description_x000D_ Suramin is an antiparasitic drug, which blocks endothelial cell proliferation and increases tyrosine phosphorylation of many signalling proteins. It is associated with urticaria, paresthesias, vomiting and neurologic toxicity. Suramin is used to treat trypanosomiasis and onchocerciasis. It functions as an inhibitor of heparanase and also exhibits anti-AIDS (acquired immunodeficiency syndrome) property._x000D_ Application_x000D_ Suramin sodium salt has been used:_x000D_ • as a potent blocker of rat P2Y2 purinergic receptor_x000D_ • to study its effects on short circuit current (Isc) across strial marginal cells_x000D_ • to show its effects on initial burst of glial activity_x000D_ • to assess its neuroprotective potential in rats_x000D_ • as a purinoceptor inhibitor, to explore the mechanism of action of extracellular adenosine triphosphate (eATP)_x000D_ Packaging_x000D_ 100, 500 mg in poly bottle_x000D_ Biochem/physiol Actions_x000D_ Suramin is a polysulfonated naphthylurea anticancer agent that inhibits tumor cell proliferation. It inhibits the activity of topoisomerase II by blocking the binding of the enzyme to DNA. It′s antiangiogenic activity may be related to its ability to bind to and inhibit the activity of several growth factors, including FGFa, FGFb, and PGDF. It uncouples G-proteins from receptors. It is an broad spectrum antagonist at P2X and P2Y purinergic receptors. Suramin has well documented antiprotozoal and anthelmintic activity.